• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prospects for oral iron chelation therapy.

作者信息

Hoffbrand A V

机构信息

Department of Haematology, Royal Free Hospital and School of Medicine, London, England.

出版信息

J Lab Clin Med. 1994 Apr;123(4):492-4.

PMID:8144997
Abstract
摘要

相似文献

1
Prospects for oral iron chelation therapy.口服铁螯合疗法的前景。
J Lab Clin Med. 1994 Apr;123(4):492-4.
2
Overview of iron chelation therapy with desferrioxamine and deferiprone.去铁胺和去铁酮铁螯合疗法概述
Hemoglobin. 2009;33 Suppl 1:S58-69. doi: 10.3109/03630260903346924.
3
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.铁螯合疗法的伦理问题及风险/效益评估：去铁酮/去铁胺联合疗法的进展以及对地拉罗司安全性、有效性和成本的担忧。
Hemoglobin. 2008;32(1-2):1-15. doi: 10.1080/03630260701726533.
4
Iron chelation therapy for patients with sickle cell disease and iron overload.镰状细胞病和铁过载患者的铁螯合疗法。
Am J Hematol. 2010 Oct;85(10):782-6. doi: 10.1002/ajh.21806.
5
[Iron-chelating treatment].
Haematologica. 1989 Oct;74(5 Suppl):241-51.
6
Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.使用去铁酮（L1）、去铁胺的ICOC联合治疗方案及新型螯合药物对地中海贫血铁过载进行有效新治疗。
Haematologica. 2006 Jun;91(6 Suppl):ELT04.
7
A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.一项使用心血管磁共振评估去铁胺与去铁酮联合治疗对重型地中海贫血患者心肌铁影响的随机、安慰剂对照、双盲试验。
Circulation. 2007 Apr 10;115(14):1876-84. doi: 10.1161/CIRCULATIONAHA.106.648790. Epub 2007 Mar 19.
8
Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload.铁螯合疗法：铁过载患者的临床疗效、经济负担及生活质量
Adv Ther. 2008 Aug;25(8):725-42. doi: 10.1007/s12325-008-0085-z.
9
Recent developments in iron chelation therapy.铁螯合疗法的最新进展。
Klin Padiatr. 2007 May-Jun;219(3):158-65. doi: 10.1055/s-2007-973845.
10
Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.输血依赖型地中海贫血患者不遵守铁螯合疗法的后果及成本：一项文献综述
Transfusion. 2007 Oct;47(10):1919-29. doi: 10.1111/j.1537-2995.2007.01416.x.

引用本文的文献

1
The Fungal Iron Chelator Desferricoprogen Inhibits Atherosclerotic Plaque Formation.真菌铁螯合剂去铁敏抑制动脉粥样硬化斑块形成。
Int J Mol Sci. 2020 Jul 3;21(13):4746. doi: 10.3390/ijms21134746.
2
Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells.亲脂性芳酰腙螯合剂 HNTMB 及其对卵巢癌细胞的多种作用。
BMC Cancer. 2010 Feb 25;10:72. doi: 10.1186/1471-2407-10-72.
3
Desferrithiocin is a more potent antineoplastic agent than desferrioxamine.去铁硫菌素是一种比去铁胺更有效的抗肿瘤药物。
Br J Pharmacol. 2002 Mar;135(6):1393-402. doi: 10.1038/sj.bjp.0704507.
4
A risk-benefit assessment of iron-chelation therapy.铁螯合疗法的风险效益评估。
Drug Saf. 1997 Dec;17(6):407-21. doi: 10.2165/00002018-199717060-00006.